PFIZER INC 8K

Pfizer Inc. reported Q2 2026 results, modest top-line growth and significant non-cash impairments, raised its 2026 revenue guidance midpoint, expanded multi-year cost-savings programs, advanced multiple pipeline and regulatory milestones, completed a major oncology licensing deal with Innovent Biologics, and announced the planned transition from CFO Dave Denton to Interim CFO Cecile Guegan in August 2026.

On August 4, 2026, Pfizer Inc. reported its second-quarter 2026 results, highlighting $15.0 billion in revenue (3% year-over-year growth, 1% operational), strong 18% operational revenue growth from launched and acquired products, and an overall shift in mix away from sharply declining COVID-19 products Comirnaty and Paxlovid. Despite a reported GAAP loss per share of $(0.04) driven primarily by $4.3 billion of non-cash intangible asset impairments (notably Phase 3 sigvotatug vedotin and Oxbryta), Pfizer delivered adjusted diluted EPS of $0.77 and reaffirmed full-year 2026 adjusted EPS guidance of $2.80–$3.00 while raising its 2026 revenue guidance midpoint by $0.5 billion to $60.5–$62.5 billion. The company expanded its cost-savings and manufacturing optimization programs, targeting an additional $1.0 billion of SG&A savings and $1.5 billion of cost-of-goods savings through 2029 (bringing expected total program net savings to $6.7 billion and $3.0 billion, respectively), with roughly $6.0 billion of associated one-time costs through 2029. Pfizer also detailed capital allocation (including $5.3 billion of R&D investment, $4.9 billion in dividends, and completion of a global licensing and collaboration agreement with Innovent Biologics, Inc. involving a $650 million upfront payment), provided a broad late-stage and pipeline update across key products such as Eliquis, Padcev, Lorbrena, Hympavzi, Ibrance, Litfulo, Talzenna, berobenatide, and pneumococcal vaccine candidates, and disclosed an upcoming finance leadership transition with CFO Dave Denton stepping down on August 15, 2026 and Cecile Guegan becoming Interim CFO effective August 16, 2026 while a search for a permanent successor proceeds.

Filing Facts

CIK

78003

Ticker

PFE

Form

8K

Source Type

fda

Accession

0000078003-26-000094

Alert Tier

7